In a series of tweets, the president addressed an unusual controversy stemming from a speech Thursday that New York Fed President John Williams delivered.Marketsread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
Earlier, Williams said in a speech that "it's better to take preventative measures than to wait for disaster to unfold."The Fedread more
The University of Michigan's preliminary print on its consumer sentiment index ticked up to 98.4, from 98.2 in June. Economists polled by Refinitiv expected the preliminary...Economyread more
The mega-cap tech stocks that have led much of the record-long bull run have started to lose steam, but investors are still giving them the benefit of the doubt.Marketsread more
Houston, we have liftoff. Fifty years ago, man landed on the moon and McDonald's and a handful of other stocks took off into the stratosphere. Two of them have more fuel in...Trading Nationread more
Amazon's PillPack was informed this week that it will soon be cut off from patient medication data, according to people familiar with the matter.Technologyread more
An Israeli cybersecurity company has reportedly developed spyware that can scrape data from the servers of Apple, Google, Facebook, Amazon and Microsoft products.Technologyread more
House Speaker Nancy Pelosi is rejecting the White House's most recent debt ceiling proposal, Bloomberg reports.Marketsread more
The country's Revolutionary Guards say they will soon releasePoliticsread more
The U.S. stock market should move higher from near-record current levels, says the co-founder of the world's largest money manager.Marketsread more
(Adds details on J&J's warning letter; updates Sientra shares)
March 19 (Reuters) - The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants.
The long-term safety of breast implants has been questioned over the years. Last month, the FDA had issued a statement https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm630863 . h t m warning doctors about a type of lymphoma linked to breast implants after receiving reports of the disease.
The agency's letters http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reu t e r s . c o m : 2 0 1 9 0 3 1 9 : n P n 7 r w b Q S a , dated March 18, highlighted issues in the companies' post-approval studies, which included evaluating the long-term performance and safety of the implants, used for breast augmentation and reconstruction procedures.
The letter https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm633710.htm to J&J's medical esthetics unit Mentor Worldwide LLC noted "several serious deficiencies" in the company's post-approval study for its MemoryShape breast implant approved in 2013.
Failure to enroll the required number of patients in the study and data inconsistencies, including poor patient accounting and missing race and ethnicity data, were identified as violations in the letter to Mentor.
Sientra had reported poor patient follow-up rate of 61 percent for the post-approval study of its Silicone Gel Breast Implants, which required the company to evaluate the study subjects annually for 10 years, according to the FDA letter https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm633719.htm.
The agency said failure to make good the violations may result in the withdrawal of the premarket approval granted to the products.
The FDA asked the companies to provide responses within 15 working days with details about how the noted violations will be corrected.
Last year, the U.S. Securities and Exchange Commission had sued Sientra's former chief executive for fraudulently concealing problems with his company's breast and other implants while raising $61.4 million in a public stock offering.
Shares of Sientra were down 1.8 percent at $8.65, while J&J shares were flat in after market trading. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber)